AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12529549 — intervention group
Group type: EXPERIMENTAL
Intervention: Unselected mononucleated cells
Number of subjects: 18
Study 12529549 — intervention group
Group type: COMPARATOR
Intervention: Serum-free versus serum-dependent culture medium
Number of subjects: 18
Study 12529549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine combinations including flt3 ligand
Number of subjects: 18
Study 10949811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic, acrylic lens: Bausch&Lomb‐Hydroview
Number of subjects: 57
Study 10949811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic, acrylic Alcon Acrysof MA60 lens
Number of subjects: 57
Study 10949811 — intervention group
Group type: COMPARATOR
Intervention: Control group (senile cataract patients)
Number of subjects: 57
Study 8971254 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercise
Number of subjects: 8
Study 8971254 — intervention group
Group type: COMPARATOR
Intervention: Leg exercise
Number of subjects: 8
Study 1532896 — intervention group
Group type: COMPARATOR
Intervention: succinylcholine
Number of subjects: 60
Study 1532896 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium
Number of subjects: 60
Study 4072599 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% prilocaine with 0.4% hyaluronic acid
Number of subjects: 0
Study 4072599 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.4% hyaluronic acid
Number of subjects: 0
Study 4072599 — intervention group
Group type: COMPARATOR
Intervention: 2% prilocaine without hyaluronic acid
Number of subjects: 0
Study 4072599 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine without hyaluronic acid
Number of subjects: 0
Study 30324849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination oxycodone (5‐mg) and acetaminophen (325‐mg) tablets, 15 tablets prescribed
Number of subjects: 219
Study 30324849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination oxycodone (5‐mg) and acetaminophen (325‐mg) tablets
Number of subjects: 219
Study 30324849 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 219
Study 29538683 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD-rich botanical extract
Number of subjects: 0
Study 29538683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26575158 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 103
Study 26575158 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HADS-A
Number of subjects: 103
Study 26575158 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HADS-D
Number of subjects: 103
Study 26575158 — intervention group
Group type: EXPERIMENTAL
Intervention: End of therapy HADS-D
Number of subjects: 103
Study 25642582 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT-S)
Number of subjects: 49
Study 25642582 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation treatment (ST)
Number of subjects: 49
Study 25642582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (BCT-S and ST)
Number of subjects: 49
Study 25063191 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ) treatment
Number of subjects: 20
Study 25063191 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels
Number of subjects: 20
Study 20470229 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin therapy
Number of subjects: 240
Study 18360068 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 50
Study 18360068 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (5 mg/day of enalapril or imidapril)
Number of subjects: 50
Study 18360068 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 15976965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy and intra-aortic balloon counterpulsation (IABP)
Number of subjects: 57
Study 15976965 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis alone
Number of subjects: 57
Study 15976965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy and intra-aortic balloon counterpulsation (IABP) in patients with Killip class III or IV
Number of subjects: 57
Study 15976965 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis alone in patients with Killip class III or IV
Number of subjects: 57
Study 12593493 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg once daily
Number of subjects: 28
Study 12593493 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 20 mg once daily
Number of subjects: 28
Study 10593132 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-coated Calcium Acetate (NCCaAc)
Number of subjects: 19
Study 10593132 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated Calcium Acetate (ECCaAc)
Number of subjects: 19
Study 10593132 — intervention group
Group type: COMPARATOR
Intervention: Phos-ex (Cablon, The Netherlands)
Number of subjects: 19
Study 8546737 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day oral bovine type II collagen (n = 30)
Number of subjects: 90
Study 8546737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day oral bovine type II collagen (n = 30)
Number of subjects: 90
Study 8546737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 90
Study 2063598 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 200 mg trapidil daily for 6 weeks
Number of subjects: 20
Study 2063598 — intervention group
Group type: COMPARATOR
Intervention: 3 x 200 mg pentoxifylline daily for 6 weeks
Number of subjects: 20
Study 6380607 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocardia rubra cell‐wall skeleton (N‐CWS)
Number of subjects: 190
Study 6380607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190
Study 30328108 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 0
Study 30328108 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 29945150 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatry intervention including foot and ankle strengthening exercises, foot orthoses, new footwear if required, and a falls prevention leaflet
Number of subjects: 1010
Study 29945150 — intervention group
Group type: COMPARATOR
Intervention: Usual podiatry treatment plus a falls prevention leaflet
Number of subjects: 1010
Study 29945150 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatry intervention
Number of subjects: 1010
Study 28078862 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary multi‐ingredient lipid‐lowering supplement (PMILLS)
Number of subjects: 40
Study 28078862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23417235 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Coping Power program (24 child sessions, 10 parent sessions)
Number of subjects: 241
Study 23417235 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster intervention (brief monthly individual contacts primarily with the children)
Number of subjects: 241
Study 19582386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturatory sling technique
Number of subjects: 41
Study 19582386 — intervention group
Group type: COMPARATOR
Intervention: Aponeurotic retropubic sling technique
Number of subjects: 41
Study 15793181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3187
Study 15793181 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3187
Study 15793181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3187
Study 15793181 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall DPP participation
Number of subjects: 3187
Study 12204928 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help with four sessions of face-to-face guidance
Number of subjects: 0
Study 12204928 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help with telephone guidance
Number of subjects: 0
Study 12204928 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help (general)
Number of subjects: 0
Study 12204928 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list comparison group
Number of subjects: 0
Study 12204928 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help
Number of subjects: 0
Study 9159363 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with brain tumors and paresis
Number of subjects: 7
Study 9159363 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 7
Study 7943590 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy with pyloroplasty (TVP)
Number of subjects: 26
Study 7943590 — intervention group
Group type: COMPARATOR
Intervention: Antiulcer operations excluding the duodenum (TV-GJ and Billroth II)
Number of subjects: 26
Study 7943590 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy with gastrojejunostomy (TV-GJ)
Number of subjects: 26
Study 7943590 — intervention group
Group type: COMPARATOR
Intervention: Billroth II gastrectomy
Number of subjects: 26
Study 2854781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intraluminal 5-FU chemotherapy and intravenous 5-FU chemotherapy (30 mg/kg intraluminally and 10 mg/kg intravenously on the first and second days postoperatively)
Number of subjects: 82
Study 2854781 — intervention group
Group type: COMPARATOR
Intervention: Control group (radical resection alone)
Number of subjects: 82
Study 2854781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intraluminal 5-FU chemotherapy
Number of subjects: 82
Study 10972454 — intervention group
Group type: EXPERIMENTAL
Intervention: Women smokers
Number of subjects: 136
Study 30299412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (SUC; 40 g)
Number of subjects: 16
Study 30299412 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitrate (NIT; 800 mg NO3)
Number of subjects: 16
Study 30299412 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (PLA)
Number of subjects: 16
Study 29188740 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinical CI
Number of subjects: 10
Study 29188740 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal auditory training
Number of subjects: 10
Study 29188740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus specific electrical stimulation
Number of subjects: 10
Study 27095106 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback (FB) condition
Number of subjects: 370
Study 27095106 — intervention group
Group type: COMPARATOR
Intervention: Treatment‐as‐Usual (TAU) condition
Number of subjects: 370
Study 24648401 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 45134
Study 21911051 — intervention group
Group type: EXPERIMENTAL
Intervention: Bu‐Fei Yi‐Shen granule combined with Shu‐Fei Tie acupoint sticking therapy
Number of subjects: 244
Study 21911051 — intervention group
Group type: COMPARATOR
Intervention: Oral sustained‐release theophylline and placebo Bu‐Fei Yi‐Shen granule combined with placebo Shu‐Fei Tie acupoint sticking therapy
Number of subjects: 244
Study 20416454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal packing (Group 1)
Number of subjects: 100
Study 20416454 — intervention group
Group type: COMPARATOR
Intervention: No pharyngeal packing (Group 2)
Number of subjects: 100
Study 17413560 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacontrol (DC, plasma conductivity targeted feedback system)
Number of subjects: 10
Study 17413560 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis (HD)
Number of subjects: 10
Study 15370670 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib combined vaccine (Group 1)
Number of subjects: 440
Study 15370670 — intervention group
Group type: COMPARATOR
Intervention: DTPa-HBV-IPV (Group 2) and Hib vaccines administered separately
Number of subjects: 440
Study 11207630 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral oestradiol valerate 2 mg/day
Number of subjects: 79
Study 11207630 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐oestradiol gel (1 mg oestradiol/day)
Number of subjects: 79
Study 11207630 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 79
Study 11207630 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 79
Study 9743769 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio learning intervention where students followed a patient with cancer for 9 months, supported by bi-monthly small-group tutorials.
Number of subjects: 0
Study 9743769 — intervention group
Group type: EXPERIMENTAL
Intervention: Students submitting portfolios for formative assessment.
Number of subjects: 0
Study 9743769 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum (Control group).
Number of subjects: 0
Study 7803676 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised physical exercise program (walking, frequency, length, intensity calculated individually)
Number of subjects: 96
Study 7803676 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised physical exercise program
Number of subjects: 96
Study 7803676 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 96
Study 3058974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg, 3 times a day
Number of subjects: 59
Study 3058974 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg, 3 times a day
Number of subjects: 59
Study 3058974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 59
Study 3058974 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 59
Study 30341842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose and rifaximin
Number of subjects: 96
Study 30341842 — intervention group
Group type: COMPARATOR
Intervention: Lactulose only (placebo)
Number of subjects: 96
Study 29202488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 12
Study 29202488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26316499 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive app (Zombies, Run)
Number of subjects: 51
Study 26316499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimmersive app (Get Running)
Number of subjects: 51
Study 26316499 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual behavior)
Number of subjects: 51
Study 23180385 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmony(®) self‐ligating lingual appliances
Number of subjects: 7
Study 23180385 — intervention group
Group type: COMPARATOR
Intervention: Incognito(®) lingual appliances
Number of subjects: 7
Study 23180385 — intervention group
Group type: EXPERIMENTAL
Intervention: Typodonts with Harmony(®) self‐ligating appliances
Number of subjects: 7
Study 23180385 — intervention group
Group type: COMPARATOR
Intervention: Typodonts with Incognito(®) appliances
Number of subjects: 7
Study 23180385 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐ligation
Number of subjects: 7
Study 23180385 — intervention group
Group type: COMPARATOR
Intervention: Non-self‐ligation
Number of subjects: 7
Study 22027699 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg Zeaxanthin (Zx)
Number of subjects: 60
Study 22027699 — intervention group
Group type: COMPARATOR
Intervention: 9 mg Lutein (L) (Faux Placebo, control group)
Number of subjects: 60
Study 22027699 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg Zx plus 9 mg L
Number of subjects: 60
Study 22027699 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Zx, Zx + L, and L)
Number of subjects: 60
Study 18781089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 21
Study 18781089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18781089 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 21
Study 16571852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored expert system
Number of subjects: 2862
Study 16571852 — intervention group
Group type: COMPARATOR
Intervention: Information-only condition
Number of subjects: 2862
Study 15543394 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 93
Study 15543394 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 93
Study 15543394 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (Control)
Number of subjects: 93
Study 11203846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract (DeTrey‐Dentsply) with etching for 30 seconds
Number of subjects: 60
Study 11203846 — intervention group
Group type: COMPARATOR
Intervention: Dyract (DeTrey‐Dentsply) without etching
Number of subjects: 60
Study 9188761 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hyperglycemia (15 mmol/l)
Number of subjects: 7
Study 9188761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) infusion (0.5 IDU/kg.h for 60 min) during hyperglycemia
Number of subjects: 7
Study 9188761 — intervention group
Group type: COMPARATOR
Intervention: Cholecystokinin (CCK) infusion (0.5 IDU/kg.h for 60 min) during normoglycemia
Number of subjects: 7
Study 9188761 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal and CCK-stimulated plasma PP concentrations during hyperglycemia
Number of subjects: 7
Study 8442581 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (Uniphyllin Continus)
Number of subjects: 19
Study 8442581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3510591 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 units of platelet concentrates (PLT)
Number of subjects: 33
Study 3510591 — intervention group
Group type: COMPARATOR
Intervention: 2 units of fresh frozen plasma (FFP)
Number of subjects: 33
Study 29696311 — intervention group
Group type: EXPERIMENTAL
Intervention: E-monitoring counseling
Number of subjects: 513
Study 29696311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus nicotine gum
Number of subjects: 513
Study 29696311 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 513
Study 27622723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 398
Study 27622723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 24820498 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (Group B)
Number of subjects: 79
Study 24820498 — intervention group
Group type: COMPARATOR
Intervention: Real-time ultrasound guided biopsy (Group A)
Number of subjects: 79
Study 23342881 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtip catheter
Number of subjects: 122
Study 23342881 — intervention group
Group type: COMPARATOR
Intervention: Air‐charged catheter
Number of subjects: 122
Study 20593957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m2
Number of subjects: 140
Study 20593957 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 20 mg/m2
Number of subjects: 140
Study 18575626 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate+amodiaquine (AS+AQ)
Number of subjects: 534
Study 18575626 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 534
Study 18575626 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate+chlorproguanil-dapsone (AS+CD)
Number of subjects: 534
Study 16042882 — intervention group
Group type: EXPERIMENTAL
Intervention: famciclovir 500 mg tid
Number of subjects: 219
Study 16042882 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 219
Study 12594973 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% grapeseed oil and 20% lavender oil in their bath for 14 days
Number of subjects: 80
Study 12594973 — intervention group
Group type: COMPARATOR
Intervention: grapeseed oil in their bath for 14 days
Number of subjects: 80
Study 9841843 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugates administered to young children (two or three primary doses)
Number of subjects: 0
Study 9841843 — intervention group
Group type: EXPERIMENTAL
Intervention: Herd immunity effect from Hib vaccination
Number of subjects: 0
Study 9841843 — intervention group
Group type: EXPERIMENTAL
Intervention: Different Hib conjugates
Number of subjects: 0
Study 9841843 — intervention group
Group type: EXPERIMENTAL
Intervention: Three primary vaccine doses
Number of subjects: 0
Study 7594337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 26
Study 7594337 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonist
Number of subjects: 26
Study 2138180 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin plus zinc
Number of subjects: 103
Study 2138180 — intervention group
Group type: COMPARATOR
Intervention: Topical 1% clindamycin phosphate (Cleocin‐T)
Number of subjects: 103
Study 428219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 1843
Study 428219 — intervention group
Group type: COMPARATOR
Intervention: Copper-T-200
Number of subjects: 1843
Study 31062156 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisionless fluorescent cholangiography (IFC)
Number of subjects: 51
Study 31077181 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent suicide attempts
Number of subjects: 288
Study 31077181 — intervention group
Group type: COMPARATOR
Intervention: Duration of illness
Number of subjects: 288
Study 31077181 — intervention group
Group type: COMPARATOR
Intervention: Low-density lipoprotein (LDL) cholesterol
Number of subjects: 288
Study 31077181 — intervention group
Group type: COMPARATOR
Intervention: Total cholesterol
Number of subjects: 288
Study 31077181 — intervention group
Group type: COMPARATOR
Intervention: Psychotic symptoms
Number of subjects: 288
Study 31077181 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 288
Study 28455510 — intervention group
Group type: EXPERIMENTAL
Intervention: NPK fertilization
Number of subjects: 3
Study 28455510 — intervention group
Group type: COMPARATOR
Intervention: NP fertilization
Number of subjects: 3
Study 28455510 — intervention group
Group type: COMPARATOR
Intervention: NK fertilization
Number of subjects: 3
Study 28455510 — intervention group
Group type: COMPARATOR
Intervention: PK fertilization
Number of subjects: 3
Study 28455510 — intervention group
Group type: COMPARATOR
Intervention: NP, NK, and PK fertilization
Number of subjects: 3
Study 26198205 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 5384